Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

28.79 +0.06 (+0.21%)
Streaming Delayed Price Updated: 11:01 AM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
From Edgewise Therapeutics
Via Business Wire
News headline image
MarketBeat Week in Review – 9/23 - 9/27
Stocks had a mostly bullish week as stimulus efforts in the U.S. and China enhanced risk-on sentiment, but next week's jobs report could spark a larger rally 
Via MarketBeat
Topics Economy
News headline image
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run? 
Via MarketBeat
News headline image
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. 
Via Benzinga
Topics Economy
News headline image
Crude Oil Gains Over 1%; Mobileye Global Shares Jump ↗
 
Via Benzinga
News headline image
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Edgewise Therapeutics is rocketing higher on positive results for its HCM combating treatment and short-covering. Expect volatility in the weeks ahead. 
Via MarketBeat
News headline image
Why Edgewise Therapeutics Stock Is Up 50% on Thursday ↗
One of the biopharma company's heart drugs performs as well as initially hoped. 
Via The Motley Fool
News headline image
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment ↗
Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic cardiomyopathy, showing the drug was well tolerated with reductions in LVOT... 
Via Benzinga
News headline image
Darden Restaurants Posts Q1 Results, Joins Tesla, Nvidia, XPeng And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip ↗
Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics. 
Via Investor's Business Daily
News headline image
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
From Edgewise Therapeutics
Via Business Wire
News headline image
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024 ↗
EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
News headline image
7 Small-Cap Stocks to Buy for Large-Scale Gains ↗
Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling. 
Via InvestorPlace
News headline image
Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs ↗
What sectors outperformed after Trump won the 2016 election, and which outperformed during his term? 
Via Investor's Business Daily
Topics Government
News headline image
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense ↗
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
Via Investor's Business Daily
News headline image
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day ↗
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM. 
Via Investor's Business Daily
News headline image
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
From Edgewise Therapeutics
Via Business Wire
News headline image
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024 ↗
EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2 ↗
 
Via Benzinga
News headline image
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
From Edgewise Therapeutics
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.